Allied Healthcare Group (ASX: AHZ) today announces it has commenced shipment of CardioCel®
into Europe after the Company received its first orders for the product from outside of Australia.
In August the Company received European CE mark approval for CardioCel® and so cleared the
final regulatory hurdle ahead of a launch and marketing of the product in this key market.
“Today we can announce we have made the first sale of CardioCel® into Europe and shipping has
commenced - a milestone development for both the Company and our lead regenerative tissue
product,” said Allied Healthcare Group’s CEO Mr Lee Rodne.
“Allied is seeking to have CardioCel® used by cardiothoracic surgeon teams across Europe for the
repair and reconstruction of cardiac defects in both adults and children.
“We will initially focus our European sales team on the major cente
1st sales in europe
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.30 |
Change
0.300(1.67%) |
Mkt cap ! $351.7M | |||
| Open | High | Low | Value | Volume |
| $18.25 | $18.30 | $18.01 | $12.33K | 679 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 300 | $18.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.30 | 247 | 2 |
View Market Depth
| Last trade - 14.56pm 04/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |